BPG is committed to discovery and dissemination of knowledge
Articles in Press
9/25/2020 5:16:59 AM | Browse: 37 | Download: 63
Publication Name World Journal of Clinical Cases
Manuscript ID 58123
Country/Territory Switzerland
Category Gastroenterology & Hepatology
Manuscript Type Observational Study
Article Title Cost-effectiveness of lutetium (177Lu) oxodotreotide vs everolimus in gastroenteropancreatic neuroendocrine tumors in Norway and Sweden
Manuscript Source Unsolicited Manuscript
All Author List Jayne Palmer and Oscar R Leeuwenkamp
Funding Agency and Grant Number
Corresponding Author Jayne Palmer, BSc, DPhil, Doctor, NA, Ossian Health Economics and Communications, Bäumleingasse 20, Basel 4051, Switzerland. smith-palmer@ossianconsulting.com
Key Words Cost; Cost-effectiveness; Neuroendocrine tumors; 177Lu-Dotatate; Sweden; Norway
Core Tip Peptide receptor radionuclide therapy with 177Lutetium oxodotreotide (177Lu-Dotatate; Lutathera), which targets the overexpression of somatostatin receptors, particularly the somatostatin receptor type 2 expressed on the surface of tumor cells in some neuroendocrine tumors (NETs), is an efficacious new treatment approach for patients with gastroenteropancreatic NETs. To be adopted into routine clinical practices, new treatments should also be cost-effective as well as efficacious. Long-term health economic analyses suggest that in Sweden and Norway 177Lu-Dotate is likely to be cost-effective and associated with minimal budget impact relative to everolimus for the treatment of unresectable or metastatic progressive midgut or pancreatic NETs.
Citation Palmer J, Leeuwenkamp OR. Cost-effectiveness of lutetium (177Lu) oxodotreotide vs everolimus in gastroenteropancreatic neuroendocrine tumors in Norway and Sweden. World J Clin Cases 2020; 8(20): 4793-4806
Received
2020-07-08 11:40
Peer-Review Started
2020-07-08 11:41
To Make the First Decision
Return for Revision
2020-08-11 15:10
Revised
2020-08-21 16:16
Second Decision
2020-09-24 12:47
Accepted by Journal Editor-in-Chief
Accepted by Company Editor-in-Chief
2020-09-25 05:16
Articles in Press
2020-09-25 05:16
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript
2020-10-19 00:54
ISSN 2307-8960 (online)
Open Access This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/
Copyright © The Author(s) 2020. Published by Baishideng Publishing Group Inc. All rights reserved.
Permissions For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website http://www.wjgnet.com